345 related articles for article (PubMed ID: 20550178)
1. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
Hara D; Tao W; Totiger TM; Pourmand A; Dogan N; Ford JC; Shi J; Pollack A
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):220-232. PubMed ID: 33964351
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging.
Javier DJ; Nitin N; Levy M; Ellington A; Richards-Kortum R
Bioconjug Chem; 2008 Jun; 19(6):1309-12. PubMed ID: 18512972
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
[TBL] [Abstract][Full Text] [Related]
7. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
9. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
10. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
Kasten BB; Liu T; Nedrow-Byers JR; Benny PD; Berkman CE
Bioorg Med Chem Lett; 2013 Jan; 23(2):565-8. PubMed ID: 23232055
[TBL] [Abstract][Full Text] [Related]
11. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
13. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
16. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
[TBL] [Abstract][Full Text] [Related]
17. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
18. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
19. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
